The global pharmaceutical dissolution testing services market is expected to register significant growth in the forecast period. The major growth factor of the pharmaceutical dissolution testing services market are increasing demand for quality products due to awareness among consumers, rising technological advancements, and the production of a large number of drugs for various chronic diseases that have to undergo dissolution testing. The existence of strong regulatory procedures, such as USP (United States Pharmacopeia) and FDA, which demand rigorous testing criteria before permission can be granted, is also acting to promote the market for pharmaceutical dissolution testers on a global scale.
The COVID-19 pandemic has greatly impacted the pharmaceutical dissolution testing sector in addition to causing a global economic slowdown. The manufacture of unique and cutting-edge pharmaceuticals and biologic goods is increasing in response to the need to combat the pandemic, which is driving the rapid expansion of pharmaceutical dissolution testing services. Instrument monitoring, validation, maintenance, and possibly repair have seen an increase in acceptance and implementation.
In terms of dosage form, the capsule and tablet segments are expected to lead the market in the forecast period as they can be easily manufactured and in large quantities, they have high physical and chemical stability, and the amount of drug delivered to the body can be controlled, making them a popular choice among manufacturers.
The North America region is expected to dominate the market in the forecast period due to presence of major market players offering Pharmaceutical Dissolution Testing Services, the expansion of the healthcare infrastructure, the rise in disease burden, which will increase the demand for drugs that will in turn increase laboratory diagnostic testing, and the R&D expenditures made by market players for the creation of novel therapeutics for chronic diseases.
The key market players include Intertek Group Plc., Avivia BV, Almac Group, Agilent Technologies, Inc., Catalent, Inc., Thermofisher Scientific Inc., Cambrex, Charles River laboratories, Boston Analytical, Pace Analytical Life Sciences, SOTAX, AMRI, and SGS SA. They are adopting various strategies like merger and acquisition, collaboration, and expansion. For instance , in March 2022, SOTAX launched a prototype that will allow performing testing conditions that are closer to human body conditions.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."